Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2014 3
2015 3
2016 7
2017 3
2018 11
2019 4
2020 3
2021 3
2022 6
2023 3
2024 8
2025 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
What is the prevalence of fear of cancer recurrence in cancer survivors and patients? A systematic review and individual participant data meta-analysis.
Luigjes-Huizer YL, Tauber NM, Humphris G, Kasparian NA, Lam WWT, Lebel S, Simard S, Smith AB, Zachariae R, Afiyanti Y, Bell KJL, Custers JAE, de Wit NJ, Fisher PL, Galica J, Garland SN, Helsper CW, Jeppesen MM, Liu J, Mititelu R, Monninkhof EM, Russell L, Savard J, Speckens AEM, van Helmondt SJ, Vatandoust S, Zdenkowski N, van der Lee ML. Luigjes-Huizer YL, et al. Among authors: zdenkowski n. Psychooncology. 2022 Jun;31(6):879-892. doi: 10.1002/pon.5921. Epub 2022 Apr 7. Psychooncology. 2022. PMID: 35388525 Free PMC article.
Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61-20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial.
Zdenkowski N, Kuper-Hommel MJJ, Niman SM, Francis PA, Baron-Hay S, Fox W, Menzies AM, Angus R, Punie K, Zardawi S, Regan MM, Loi S. Zdenkowski N, et al. Lancet Oncol. 2025 Mar;26(3):367-377. doi: 10.1016/S1470-2045(24)00757-5. Lancet Oncol. 2025. PMID: 40049198 Clinical Trial.
Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Electronic address: bc.overview@ndph.ox.ac.uk; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Electronic address: bc.overview@ndph.ox.ac.uk, et al. Lancet. 2025 Aug 9;406(10503):603-614. doi: 10.1016/S0140-6736(25)01013-X. Lancet. 2025. PMID: 40783288 Free article.
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial.
Pfeiler G, Hlauschek D, Mayer EL, Deutschmann C, Kacerovsky-Strobl S, Martin M, Meisel JL, Zdenkowski N, Loibl S, Balic M, Park H, Prat A, Isaacs C, Bajetta E, Balko JM, Bellet-Ezquerra M, Bliss J, Burstein H, Cardoso F, Fohler H, Foukakis T, Gelmon KA, Goetz M, Haddad TC, Iwata H, Jassem J, Lee SC, Linderholm B, Los M, Mamounas EP, Miller KD, Morris PG, Munzone E, Gal-Yam EN, Ring A, Shepherd L, Singer C, Thomssen C, Tseng LM, Valagussa P, Winer EP, Wolff AC, Zoppoli G, Machacek-Link J, Schurmans C, Huang X, Gauthier E, Fesl C, Dueck AC, DeMichele A, Gnant M; PALLAS Groups and Investigators. Pfeiler G, et al. Among authors: zdenkowski n. J Clin Oncol. 2023 Nov 20;41(33):5118-5130. doi: 10.1200/JCO.23.00126. Epub 2023 Aug 9. J Clin Oncol. 2023. PMID: 37556775 Clinical Trial.
Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer.
Shinn E, Zahrieh D, DeMichele A, Zdenkowski N, Lemieux J, Mao J, Bjelic-Radisic V, Naughton MJ, Pfeiler G, Gelmon K, Balko JM, Egle D, Zoppoli G, Traina T, Jimenez MM, Novoa SA, Haddad T, Chan A, Ring A, Wolff A, Symmans WF, Ponce Lorenzo J, Sabanathan D, Burstein HJ, Nowecki ZI, Pristauz-Telsnigg G, Brufsky A, Bellet-Ezquerra M, Foukakis T, Novik Y, Rubovszky G, Singer CF, Muehlbacher K, Filho OM, Goulioti T, Law E, Partridge AH, Carey LA, Zoroufy A, Hlauschek D, Fesl C, Mayer EL, Gnant M. Shinn E, et al. Among authors: zdenkowski n. Breast Cancer Res Treat. 2025 Jun;211(2):385-397. doi: 10.1007/s10549-025-07653-2. Epub 2025 Mar 27. Breast Cancer Res Treat. 2025. PMID: 40140172 Clinical Trial.
Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109).
Naughton MJ, Zahrieh DM, Gnant M, Zdenkowski N, Lemieux J, Mao JJ, Bjelic-Radisic V, Shinn E, Balic M, Thomssen C, Meisel JL, Ruiz GM, Loibl S, Isaacs C, Cameron D, Henao-Carrasco FM, Goetz MP, Singer CF, Werutsky G, Rugo HS, Vetter M, Tseng LM, Miller K, Fitzal F, Gil Gil JM, Park H, Linderholm B, Bajetta E, Dayao Z, Prat A, Ehrhardt K, Metzger O, Arahmani A, Law EH, Partridge AH, Carey LA, Zoroufy A, Dueck AC, O'Brien P, Hlauschek D, DeMichele A, Mayer EL. Naughton MJ, et al. Among authors: zdenkowski n. ESMO Open. 2025 Jun;10(6):105120. doi: 10.1016/j.esmoop.2025.105120. Epub 2025 Jun 4. ESMO Open. 2025. PMID: 40472660 Free PMC article. Clinical Trial.
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]).
DeMichele A, Dueck AC, Hlauschek D, Martin M, Burstein H, Pfeiler G, Zdenkowski N, Wolff A, Bellet-Ezquerra M, Winer E, Balic M, Miller K, Colleoni M, Lake D, Rubovsky G, Cameron D, Balko J, Singer CF, Nowecki Z, Iwata H, Wolmark N, Parraga KA, Rugo H, Steger GG, Traina T, Werutsky G, Czajkowska D, Metzger O, El-Abed S, Theall KP, Lu RD, O'Brien P, Fesl C, Mayer E, Gnant M. DeMichele A, et al. Among authors: zdenkowski n. Breast Cancer Res. 2025 Jan 23;27(1):12. doi: 10.1186/s13058-024-01941-3. Breast Cancer Res. 2025. PMID: 39849600 Free PMC article. Clinical Trial.
Systemic treatment of HER2-positive metastatic breast cancer: a systematic review.
Wilcken N, Zdenkowski N, White M, Snyder R, Pittman K, Mainwaring P, Green M, Francis P, De Boer R, Colosimo M, Chua S, Chirgwin J, Beith J, Bell R. Wilcken N, et al. Among authors: zdenkowski n. Asia Pac J Clin Oncol. 2014 Jun;10 Suppl S4:1-14. doi: 10.1111/ajco.12206. Asia Pac J Clin Oncol. 2014. PMID: 24797445
A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trials.
Potter S, Avery K, Ahmed R, de Boniface J, Chatterjee S, Dodwell D, Dubsky P, Federmann J, Finestone S, Gnant M, Hlauschek D, Iwata H, Jiang MY, Kaidar-Person O, Lee HB, MacKenzie M, Meyn A, Poortmans P, Poulakaki F, Richardson AL, Sepulveda KA, Spillane AJ, Thompson AM, Werutsky G, Wittmann P, Wright JL, Zdenkowski N, Cowan K, McIntosh SA; PRECEDENT Study Group. Potter S, et al. Among authors: zdenkowski n. NPJ Breast Cancer. 2025 Oct 28;11(1):116. doi: 10.1038/s41523-025-00824-w. NPJ Breast Cancer. 2025. PMID: 41152314 Free PMC article.
Feasibility and population exposure of 5-fluorouracil using therapeutic drug monitoring (PREDICT-5FU): A multicentre clinical trial.
Glewis S, Michael M, Gurney H, Olver I, Zdenkowski N, Ackland S, Kukard C, Jayawardana M, Silva SSM, Alexander M, Tie J, Galettis P, Martin JH. Glewis S, et al. Among authors: zdenkowski n. Br J Clin Pharmacol. 2025 Jul;91(7):1965-1974. doi: 10.1002/bcp.70006. Epub 2025 Feb 23. Br J Clin Pharmacol. 2025. PMID: 39988750 Free PMC article. Clinical Trial.
59 results